A Study to Evaluate the Safety of AB-1003 (Previously LION-101) in Subjects With Genetic Confirmation of LGMD2I/R9 (Part1) | MicrobiomeTrials← Back to trialsNCT05230459
A Study to Evaluate the Safety of AB-1003 (Previously LION-101) in Subjects With Genetic Confirmation of LGMD2I/R9 (Part1)
RecruitingPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2023-05-15Est. Completion: 2028-12
Enrollment target: 10 participants Locations- University of California - Irvine, Irvine, California, United States
- University of Iowa, Iowa City, Iowa, United States
- University of Kansas Medical Center, Kansas City, Kansas, United States
- Kennedy Krieger Institute, Baltimore, Maryland, United States
- VCU, Richmond, Virginia, United States
- University of Washington Medical Center, Seattle, Washington, United States
Other microbiome trials you might be interested in
LGMD2I
BBP-418 is being developed for the treatment of patients with Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I). This is a…
Richmond, United StatesEst. completion Nov 1, 2026
Limb-Girdle Muscular DystrophySocial CompetenceSelf EsteemHealth Related Quality of LifeSocial Skills
This clinical trial aims to evaluate the efficacy of a telecare-mediated psychosocial and cognitive intervention for chi…
Bilbao, SpainEst. completion Dec 30, 2026
myTomorrows (see link below in reference section)
Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I)
This is an open-label extension (rollover) study designed to evaluate the long-term safety and efficacy of BBP-418 (ribi…
Little Rock, United StatesEst. completion Oct 2030